Vera Therapeutics
Prezzo: 34.26Società e modello di business
Vera Therapeutics is a biotechnology company focused on developing innovative therapies for patients with serious autoimmune diseases. Its core products include treatments targeting conditions such as IgA nephropathy and other related disorders. The company primarily generates revenue through the development and potential commercialization of its therapeutic candidates, which are currently in various stages of clinical trials.
Profilo di investimento
The investment profile of Vera Therapeutics is more aligned with growth investors, given its focus on developing novel therapies in the biotech sector. The company does not currently offer dividends, and its financial performance indicates a higher risk profile. Investors may consider the stock for potential long-term capital appreciation, but should be aware of the inherent volatility and uncertainties associated with clinical development.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- -5.54 Rischio
- Sorpresa EPS
- -27.2% peggio del previsto
- Volatilità 20g
- 4.0% stabile
Impatto della previsione
negativoTraccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-01 02:53 | Mantieni | Vendi | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-24 02:54 | Vendi | Mantieni | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-16 02:47 | Mantieni | Vendi | Weak fundamentals and negative momentum raise significant concerns. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-06-02 19:56 | Jefferies | Aggiorna | — → 60 | 31.26 |
| 2026-06-02 15:15 | Goldman Sachs | Aggiorna | — → 90 | 32.135 |
| 2026-05-15 12:25 | Evercore ISI | Target abbassato | 95 → 91 | 38.5386 |
Ancora nulla